Innate immunity triggers IL-32 expression by fibroblast-like synoviocytes in rheumatoid arthritis

Arthritis Research and Therapy

Volumn 12, Issue 4, 2010, Pages

  Alsaleh, Ghada ^a,b   Sparsa, Laetitia ^a,b   Chatelus, Emmanuel ^a,b   Ehlinger, Mathieu ^b   Gottenberg, Jacques Eric ^a,b   Wachsmann, Dominique ^a,b   Sibilia, Jean ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM LIPOPROTEIN; DOUBLE STRANDED RNA; GAMMA INTERFERON; HYALURONIC ACID; INTERLEUKIN 1BETA; INTERLEUKIN 32; INTERLEUKIN 32 BETA; INTERLEUKIN 32 DELTA; INTERLEUKIN 32 GAMMA; INTERLEUKIN 6; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; LIPOPROTEIN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; IL32 PROTEIN, HUMAN; INTERFERON INDUCING AGENT; INTERLEUKIN DERIVATIVE; MESSENGER RNA; TLR2 PROTEIN, HUMAN; TLR3 PROTEIN, HUMAN;

ARTHRITIS; ARTICLE; CELL ISOLATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FIBROBLAST LIKE SYNOVIOCYTE; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; INNATE IMMUNITY; NUCLEOTIDE SEQUENCE; PATHOGENESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; SYNOVIOCYTE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; DRUG POTENTIATION; FIBROBLAST; GENETICS; IMMUNOLOGY; METABOLISM; SYNOVIUM;

ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DRUG SYNERGISM; FIBROBLASTS; GENE EXPRESSION; HUMANS; IMMUNITY, INNATE; INTERFERON INDUCERS; INTERFERON-GAMMA; INTERLEUKINS; LIPOPOLYSACCHARIDES; POLY I-C; RNA, MESSENGER; SYNOVIAL MEMBRANE; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77954301095     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3073     Document Type: Article

References (36)

1. Firestein GS. Evolving concept of rheumatoid arthritis. Nature 2003, 423:356-361. 10.1038/nature01661, 12748655.
2. Dahl CA, Schall RP, He H, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol 1992, 148:597-603.
3. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: a cytokine and inducer of TNF-α. Immunity 2005, 22:131-142.
4. Netea MG, Lewis EC, Azam T, Joosten LA, Jaekal J, Bae SY, Dinarello CA, Kim SH. Interleukin-32 induces the differentiation of monocytes into macrophage-like cells. Proc Natl Acad Sci USA 2008, 105:3515-3520. 10.1073/pnas.0712381105, 2265135, 18296636.
5. Netea MG, Azam T, Ferwerda G, Girardin SE, Walsh M, Park JS, Abraham E, Kim JM, Yoon DY, Dinarello CA, Kim S. IL-32 synergizes with nucleotide oligomerization domain 1(NOD1) and NOD2 ligands for IL-1β and IL-6 production through a caspase 1-dependent mechanism. Proc Natl Acad Sci U S A 2005, 102:16309-16314. 10.1073/pnas.0508237102, 1283464, 16260731.
6. Nold MF, Nold-Petry CA, Pott GB, Zepp JA, Saavedra MT, Kim SH, Dinarello CA. Endogenous IL-32 controls cytokine and HIV-1 production. J Immunol 2008, 181:557-565.
7. Netea MG, Azam T, Lewis EC, Joosten LA, Wang M, Langenberg D, Meng X, Chan ED, Yoon DY, Ottenhoff T, Kim SH, Dinarello CA. Mycobacterium tuberculosis induces interleukin-32 production through a caspase- 1/IL-18/interferon-γ-dependent mechanism. PLoS Med 2006, 3:e277. 10.1371/journal.pmed.0030277, 1539091,1539091, 16903774.
8. Fantini MC, Monteleone G, MacDonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis 2007, 13:1419-1423. 10.1002/ibd.20212, 17712836.
9. Shioya M, Nishida A, Yagi Y, Ogawa A, Tsujikawa T, Kim-Mitsuyama S, Takayanagi A, Shimizu N, Fujiyama Y, Andoh A. Epithelial overexpression of interleukin-32α in inflammatory bowel disease. Clin Exp Immunol 2007, 149:480-486. 2219317, 17590175.
10. Joosten LA, Netea MG, Kim SH, Yoon DY, Oppers-Walgreen B, Radstake TR, Barrera P, van de Loo FA, Dinarello CA, van den Berg WB. IL-32, a proinflammatory cytokine in rheumatoid arthritis. Proc Natl Acad Sci USA 2006, 103:3298-3303. 10.1073/pnas.0511233103, 1413916, 16492735.
11. Cagnard N, Letourneur F, Essabbani A, Devauchelle V, Mistou S, Rapinat A, Decraene C, Fournier C, Chiocchia G. Interleukin-32, CCL2, PF4F1 and GD10 are the only cytokine/chémokines genes differentially expressed by in vitro cultured rheumatoid and osteoarthritis fibroblast-like synoviocytes. Eur Cytokine Netw 2005, 16:289-292.
12. Muller-Ladner U, Ospelt C, Gay S, Distler O, Pap T. Cells of the synovium in rheumatoid arthritis: synovial fibroblasts. Arthritis Res Ther 2007, 9:223-230. 10.1186/ar2337, 2246247, 18177509.
13. Pierer M, Rethage J, Seibl R, Lauener R, Brentano F, Wagner U, Hantzschel H, Michel BA, Gay RE, Gay S, Kyburz D. Chemokine secretion of rheumatoid arthritis synovial fibroblasts stimulated by Toll-like receptor 2 ligands. J Immunol 2004, 172:1256-1265.
14. Jung YO, Cho ML, Kang CM, Jhun JY, Park JS, Oh HJ, Min JK, Park SH, Kim HY. Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. Immunol Lett 2007, 109:21-27. 10.1016/j.imlet.2006.12.006, 17289161.
15. Kyburz D, Rethage J, Seibl R, Lauener R, Gay RE, Carson DA, Gay S. Bacterial peptidoglycans but not CpG oligodeoxynucleotides activate synovial fibroblasts by Toll-like receptor signalling. Arthritis Rheum 2003, 48:642-650. 10.1002/art.10848, 12632416.
16. Ospelt C, Brentano F, Rengel Y, Stanczyk J, Kolling C, Tak PP, Gay RE, Gay S, Kyburz D. Overexpression of Toll-like receptors 3 and 4 in synovial tissue from patients with early rheumatoid arthritis: Toll-like receptor expression in early and longstanding arthritis. Arthritis Rheum 2008, 58:3684-3692. 10.1002/art.24140, 19035519.
17. Alsaleh G, Messer L, Semaan N, Boulanger N, Gottenberg JE, Sibilia J, Wachsmann D. BAFF synthesis by rheumatoid synoviocytes is positively controlled by α5β1 integrin stimulation and is negatively regulated by tumor necrosis factor-α and Toll-like receptor ligands. Arthritis Rheum 2007, 56:3202-3214. 10.1002/art.22915, 17907168.
18. Ohata J, Zvaifler NJ, Nishio M, Boyle DL, Kalled SL, Carson DA, Kipps TJ. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005, 174:864-870.
19. Dechanet J, Taupin JL, Chomarat P, Rissoan MC, Moreau JF, Banchereau J, Miossec P. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur J Immunol 1994, 24:3222-3228. 10.1002/eji.1830241247, 7805751.
20. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324. 10.1002/art.1780310302, 3358796.
21. Neff L, Zeisel M, Sibilia J, Scholler-Guinar M, Klein JP, Wachsmann D. NF-κB and the MAPkinase/AP-1 pathways are both involved in interleukin-6 and interleukin-8 expression in fibroblast-like synoviocytes stimulated by protein I/II, a modulin from oral streptococci. Cell Microbiol 2001, 3:703-712. 10.1046/j.1462-5822.2001.00148.x, 11580755.
22. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983, 65:55-63. 10.1016/0022-1759(83)90303-4, 6606682.
23. Semaan N, Alsaleh G, Gottenberg JE, Wachsmann D, Sibilia J. Etk/BMX, a Btk family tyrosine kinase and Mal contribute to the cross talk between MyD88 and FAK pathways. J Immunol 2008, 180:3485-3491.
24. Robinson CM, Hale PT, Carlin JM. NFκB activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-γ and tumor necrosis factor-α. Cytokine 2006, 35:53-61. 10.1016/j.cyto.2006.07.007, 16931033.
25. Ohmori Y, Schreiber RD, Hamilton TA. Synergy between interferon-γ and tumor necrosis factor-α in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor κB. J Biol Chem 1997, 272:14899-14907. 10.1074/jbc.272.23.14899, 9169460.
26. Mun SH, Kim JW, Nah SS, Ko NY, Lee JH, Kim JD, Kim do K, Kim HS, Choi JD, Kim SH, Lee CK, Park SH, Kim BK, Kim HS, Kim YM, Choi WS. Tumor necrosis factor alpha-induced interleukin-32 is positively regulated via the Syk/protein kinase Cdelta/JNK pathway in rheumatoid synovial fibroblasts. Arthritis Rheum 2009, 60:678-685. 10.1002/art.24299, 19248119.
27. Shoda H, Fujio K, Yamaguchi Y, Okamoto A, Sawada T, Kochi Y, Yamamoto K. Interactions between IL-32 and tumor necrosis factor-α contribute to the exacerbation of immune-inflammatory diseases. Arthritis Res Ther 2006, 8:R166. 10.1186/ar2074, 1794509, 17078892.
28. Goronzy JJ, Weyand CM. Rheumatoid arthritis. Immunol Rev 2005, 204:55-73. 10.1111/j.0105-2896.2005.00245.x, 15790350.
29. Kasperkovitz PV, Verbeet NL, Smeets TJ, van Rietschoten JG, Kraan MC, van der Pouw Kraan TC, Tak PP, Verweij CL. Activation of the STAT1 pathway in rheumatoid arthritis. Ann Rheum Dis 2004, 63:233-293. 10.1136/ard.2003.013276, 1754903, 14962955.
30. Schulze-Koops H, Kalden JR. The balance of Th1/Th2 cytokines in rheumatoid arthritis. Best Pract Res Clin Rheumatol 2001, 15:677-691. 10.1053/berh.2001.0187, 11812015.
31. Choi JD, Bae SY, Hong JW, Azam T, Dinarello CA, Her E, Choi WS, Kim BK, Lee CK, Yoon DY, Kim SJ, Kim SH. Identification of the most active interleukin-32 isoform. Immunology 2009, 126:535-542. 10.1111/j.1365-2567.2008.02917.x, 2673365, 18771438.
32. Gorelik L, Gilbride K, Dobles M, Kalled SL, Zandman D, Scott ML. Normal B cell homeostasis requires B cell activation factor production by radiation-resistant cells. J Exp Med 2003, 198:937-945. 10.1084/jem.20030789, 2194202, 12975458.
33. Elias J, Krol ACR, Freundlich B, Sampson M. Regulation of human lung fibroblast glycosaminoglycan production by recombinant interferons, tumor necrosis factor, and lymphotoxin. J Clin Invest 1988, 81:325-333. 10.1172/JCI113324, 329574, 2448341.
34. Jiang D, Liang J, Noble PW. Hyaluronan in tissue injury and repair. Annu Rev Cell Dev Biol 2007, 23:435-461. 10.1146/annurev.cellbio.23.090506.123337, 17506690.
35. Midwood K, Sacre S, Piccinini AM, Inglis J, Trebaul A, Chan E, Drexler S, Sofat N, Kashiwagi M, Orend G, Brennan F, Foxwell B. Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009, 15:774-780. 10.1038/nm.1987, 19561617.
36. Brentano F, Schorr O, Gay RE, Gay S, Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like-receptor 3. Arthritis Rheum 2005, 52:2656-2665. 10.1002/art.21273, 16142732.